TXG compared with ARCT: revenue, margins and what each company keeps, and the suppliers and customers both name

TXG10x Genomics, Inc.

Mkt capRevenueRevenue

ARCTArcturus Therapeutics Holdings Inc.

Mkt capRevenueRevenue

Compare

TXG10x Genomics, Inc.

ARCTArcturus Therapeutics Holdings Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

TXG

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±19.0%▲+2.10%×0.11

Q2 FY26±14.8%▲+14.10%×0.95

Q1 FY26±14.4%▼−3.66%×0.26

Feb 13 '26±19.1%▲+3.48%×0.18

ARCT

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±16.3%▲+10.58%×0.65

Q2 FY26±21.8%▲+21.88%×1.00

= impliedTXG realized, solidARCT realized, hatchedOne scale, both sides: full bar = 22%× = |realized| ÷ impliedSource: market data

May 8 '26

±15.5%

▲+3.60%

×0.23

Q1 FY26±18.3%▼−4.17%×0.23

TXG10x Genomics, Inc.

59.06▲+1.72%· post 59.44

Mkt cap$7.8BRevenue$151MQ3 FY26Revenue$643MFY25

ARCTArcturus Therapeutics Holdings Inc.

10.36▲+10.67%· post 10.36

ClosedNov 6 '26

Mkt cap$298.3MRevenue$18MQ3 FY26Revenue$82MFY25

Compare

ClosedNov 6 '26

TXG10x Genomics, Inc.

ARCTArcturus Therapeutics Holdings Inc.

59.06▲+1.72%post 59.44

Price

10.36▲+10.67%post 10.36

$7.8B

Mkt cap

$298.3M

Q3 FY26$151M

Revenue

$18MQ3 FY26

FY25$643M

Revenue

$82MFY25

TXG59.06▲+1.72%vsARCT10.36▲+10.67%ClosedNov 6 '26